Retrospective Study

Bacterobilia in pancreatic surgery-conclusions for perioperative antibiotic prophylaxis

Colin Markus Krüger, Ulrich Adam, Thomas Adam, Axel Kramer, Claus D Heidecke, Frank Makowiec, Hartwig Riediger

ORCID number: Colin Markus Krüger (0000-0003-4976-870X); Ulrich Adam (0000-0002-6649-0513); Thomas Adam (0000-0002-7658-9240); Axel Kramer (0000-0003-4193-2149); Claus D Heidecke (0000-0001-8664-9537); Frank Makowiec (0000-0003-0012-3775); Hartwig Riediger (0000-0003-2615-8853).

Author contributions: Krüger CM contributed to design of the study, acquisition and analysis of data, and writing of manuscript; Adam U contributed to performing of procedures, acquisition of data, and critical review of manuscript; Adam T contributed to acquisition of data and critical review of manuscript; Kramer A contributed to design of the study, analysis of data, interpretation of data, writing of manuscript, and reviewing the manuscript; Heidecke CD contributed to interpretation of data and critical review of manuscript; Makowiec F contributed to interpretation of data and critical review of manuscript; Riediger H contributed to design of the study, performing of procedures, analysis and interpretation of data, and writing of manuscript.

Institutional review board statement: The study was only reviewed and approved by the Review Board of Brandenburg Medical School.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used.

Colin Markus Krüger, Department of Surgery, Immanuel Hospital Rüdersdorf, Berlin 15562, Germany
Ulrich Adam, Hartwig Riediger, Department of General Surgery, Vivantes-Humboldt hospital, Berlin 13503, Germany
Thomas Adam, Department of Microbiology, Labor Berlin GmbH, Berlin 13353, Germany
Axel Kramer, Institute of Hygiene and Environmental Medicine, University Medicine Greifswald, Greifswald 17495, Mecklenburg Vorpommern, Germany
Claus D Heidecke, Department of Surgery, Clinic of General, Visceral, Vascular and Thoracic Surgery, University Medicine Greifswald, Greifswald 17475, Mecklenburg Vorpommern, Germany
Frank Makowiec, Section of clinical risk assessment, University hospital of Freiburg, Freiburg 79106, Baden-Württemberg, Germany
Corresponding author: Colin Markus Krüger, FACS, MD, PhD, Chief Physician, Postdoc, Surgeon, Department of Surgery, Immanuel Hospital Rüdersdorf, Seebad 82/83, Berlin 15562, Germany. cm.krueger@immanunel.de
Telephone: +49-1718-151480

Abstract

BACKGROUND
Jaundice or preoperative cholestasis (PC) are typical symptoms of pancreatic masses. Approximately 50% of patients undergo preoperative biliary drainage (PBD) placement. PBD is a common cause of bacterobilia (BB) and is a known surgical site infection risk factor. An adjustment of preoperative antibiotic prophylaxis (PAP) may be reasonable according to the profile of BB. For this, we examined the microbiological findings in routine series of patients.

AIM
To investigate the incidence and profile of biliary bacterial colonization in patients undergoing pancreatic head resections.

METHODS
In the period from January 2009 to December 2015, 285 consecutive pancreatic head resections were performed. Indications for surgery were malignancy (71%), chronic pancreatitis (18%), and others (11%). A PBD was in 51% and PC was in
42%. The standard PAP was ampicillin/sulbactam. Intraoperatively, a smear was taken from the hepatic duct. An analysis of the isolated species and resistograms was performed. Patients were categorized according to the presence or absence of PC (PC+/PC-) and PBD (PBD+/PBD-). Antibiotic efficiency was analyzed for standard PAP and possible alternatives.

RESULTS
BB was present in 150 patients (53%). BB was significantly more frequent in PBD+ (n = 120) than in PBD- (n = 30), P < 0.01. BB was present both in patients with PC and without PC: (PBD-/PC+: 18%, PBD-/PC+: 30%, PBD+/PC+: 88%, PBD+/PC+: 80%). BB was more frequent in malignancy (56%) than in chronic pancreatitis (45%). PBD, however, was the only independent risk factor in multivariate analysis. In total, 357 pathogens (342 bacteria and 15 fungi) were detected. The five most common groups (n = 256, 74.8%) were Enterococcus spp. (28.4%), Streptococcus spp. (16.9%), Klebsiella spp. (12.6%), Escherichia coli (10.5%), and Enterobacter spp. (6.4%). A polymicrobial BB (PBD+: 77% vs PBD-: 40%, P < 0.01) and a more frequent detection of Enterococcus (P < 0.05) was significantly associated with PBD+. In PBD+, the efficiency of imipenem and piperacillin/tazobactam was significantly higher than that of the standard PAP (P < 0.01).

CONCLUSION
PBD-/PC- and PBD-/PC+ were associated with a low rate of BB, while PBD+ was always associated with a high rate of BB. In PBD+ patients, BB was polymicrobial and more often associated with Enterococcus. In PBD+, the spectrum of potential bacteria may not be covered by standard PAP. A more potent alternative for prophylactic application, however, was not found.

Key words: Pancreatic surgery; Bacteriobilia; Antibiotic prophylaxis; Cholestasis; Cholangiopancreatography; Endoscopic retrograde

INTRODUCTION
With modern tomography techniques that yield cross-sectional images, a sufficiently predictive prognosis for the operability of pancreatic masses is now possible. A purely diagnostic endoscopic retrograde cholangiopancreatography (ERCP) is thus obsolete. In preoperative cholestasis (PC), the indication for preoperative biliary drainage (PBD) may exist. Often, however, the indication for ERCP is made even before operability has been determined. For example, an analysis of Medicare patients (1992-2007) showed that one in two patients already has a PBD at the time of the surgical
The disadvantage is that ERCP leads almost always to bacterobilia (BB)\(^2\)\(^-\)\(^4\). BB is a risk factor (up to factor 2) for surgical site infection\(^5\)\(^-\)\(^9\).

According to the current guideline recommendations for pancreatic carcinoma, preoperative ERCP shall only be carried out if cholangitis is present or if surgery cannot be performed soon. A basic indication for preoperative antibiotic prophylaxis (PAP) in pancreatic resections is given regardless of the PBD status\(^8\). In the present study, the collected microbiological data are used to investigate whether a differentiated recommendation for PAP can be derived.

### MATERIALS AND METHODS

In the period from January 2009 to December 2015, 285 pancreatic head resections were performed at the Vivantes-Humboldt-hospital in Berlin. Pylorus preserving pancreateoduodenectomy was the standard procedure (\(n = 259; 91\%\)) and Whipple was only performed in selected cases (\(n = 26; 9\%\)). The morbidity was 59\% (\(n = 169\)) and the mortality was 3.8\% (\(n = 11\)).

Intraoperatively, a standard aseptic smear of the bile fluid was obtained after the hepatocholedochal duct was severed on average 90 min after skin incision. It was then used for routine microbiological diagnostics.

During the study period, preoperative ERCP was performed in case of cholestasis due to evaluation of the initially treating gastroenterologist. Under surgical surveillance, it was always performed in patients with relevantly elevated bilirubin (>8 mg/dL) and if a pancreas head resection could not be performed promptly. According to earlier data, serum bilirubin above 5 mg/dL already reduces liver function and thus a PBD is recommended\(^10\).

During the study period, antibiotics were administered as follows: The standard PAP (ampicillin-sulbactam) was administered 30 min before the skin incision, with a second dose after 4 h of surgery. In the case of penicillin allergy, ciprofloxacin and metronidazole were used. If a postoperative infection was suspected, empirical treatment with piperacillin/tazobactam was carried out, which was adjusted after receiving the result of the smear.

The microbiological specimens were examined according to standard microbiological procedures. Sensitivity and resistance for the tested antibiotics were analyzed in this study. Intermediate sensitivity was considered as resistance according to clinical routine. The number of detected sensitivities and resistances was related to the number of bacteria in each group, even though not all antibiotics were tested for all genera. This procedure allowed comparability of the groups. The results are presented as "antimicrobial efficiency" (AE: Sensitivity in %/resistance in %).

All perioperative and microbiological data were collected in a local scientific database (IBM SPSS Statistics, IBM, version 22). For the significance calculation, both the Chi-squared and McNemar tests were used. An additional binary logistic regression analysis was performed. The graphs were created with the program "GraphPad Prism" (GraphPad Software). The workgroup affirms that the statistical review of the study was performed by a biomedical statistician.

The study defined the presence of a PC at a measured serum value above the bilirubin standard (1.2 mg/dL) in the final check prior to surgery. Some patients had a completely recovered cholestasis after placement of a biliary drainage. They were classified as PBD+ and PC-. Patient data were divided into 4 groups according to clinical criteria: PBD-/PC-, PBD-/PC+, PBD+/PC-, and PBD+/PC+.

### RESULTS

The surgical treatment data are summarized in Table 1. BB was present in 150 patients (53\%). In multivariate analysis of all factors from Table 1, only PBD was disclosed as an independent risk factor (\(P < 0.01\)).

A total of 357 isolates were cultivated (342 bacteria, 15 fungi). With PBD+, BB was significantly more common than with PBD- (BB for PBD+: \(n = 120; 83.3\%\) vs BB for PBD-: \(n = 30; 21.4\%\), \(P < 0.01\)). In the subgroup PBD+, the BB rate was high regardless of the presence of cholestasis (BB for PC+: 80\% and with PC-: 88\%). In the subgroup PC+ (\(n = 120\)), the BB rate with PBD+ was significantly higher compared to PBD- (PBD+/PC+: \(n = 60; 80\%\) vs PBD-/PC+: \(n = 13; 30\%\), \(P < 0.01\)). In the four clinical groups, the incidence of BB with PBD-/PC- was 18\%, with PBD-/PC+ 30\%, with PBD+/PC- 88\% and with PBD+/PC+ 80\% (Table 2).

Of 342 bacteria, the five most commonly isolated (TOP5; \(n = 256; 74.8\%\)) represented about three-quarters of all pathogens, and included the following genera:


**Table 1 Surgical treatment data from 285 patients with pancreatic head resection**

| Indications       | All patients, n = 285 (%) | With bacteriobilia (BB+), n = 150 (%) | Without bacteriobilia (BB-), n = 135 (%) | P value |
|-------------------|---------------------------|---------------------------------------|---------------------------------------|---------|
| Malignancy        | n = 202 (71)              | n = 114 (56)<sup>a</sup>              | n = 88 (44)                           | <0.05   |
| cP<sup>b</sup>    | n = 51 (18)               | n = 23 (45)                           | n = 28 (55)                           | 0.23    |
| Others            | n = 32 (11)               | n = 13 (41)                           | n = 19 (59)                           | 0.15    |
| Biliary drainage  |                           |                                       |                                       |         |
| PBD+              | n = 144 (51)              | n = 120 (83)<sup>b</sup>              | n = 24 (17)                           | <0.01   |
| PBD-              | n = 141 (49)              | n = 30 (21)<sup>a</sup>               | n = 111 (79)                          |         |
| Cholestasis       |                           |                                       |                                       |         |
| PC+               | n = 120 (42)              | n = 73 (61)<sup>a</sup>               | n = 47 (39)                           | 0.02    |
| PC-               | n = 165 (58)              | n = 77 (47)<sup>a</sup>               | n = 88 (53)                           |         |

<sup>a</sup>P = Chronic pancreatitis.
<sup>b</sup>P < 0.05 vs BB-.
<sup>c</sup>P < 0.01 vs BB-.
<sup>d</sup>P = 0.02 vs BB-. PBD: Preoperative biliary drainage; PC: Preoperative cholestasis; BB: Bacteriobilia.

*Enterococcus* (n = 97), *Streptococcus* (n = 58), *Klebsiella* (n = 43), *Escherichia* (n = 36), and *Enterobacter* spp. (n = 22). In contrast, there were 13 different genera with a smaller number of cases (Varia: n = 86, 25.2%): *Staphylococcus* (n = 21), *Citrobacter* (n = 14), *Bacteroides* (n = 11), *Prevotella* (n = 8), *Lactobacillus* (n = 5), *Pseudomonas* (n = 4), *Aeromonas* (n = 3), *Raoultella* (n = 3), *Morganella* (n = 2), *Clostridium* (n = 2), *Proteus* (n = 2), *Fusobacterium* (n = 2), *Hafnia* (n = 2), *Proteus* (n = 2), *MRSA* (n = 2), *Stenotrophomonas* (n = 1), *Achromobacter* (n = 1), *Lactococcus* (n = 1), *Gemella* (n = 1), and *Rothia* spp. (n = 1).

Four species were multi-resistant bacteria (two MRSA and two triple-resistant *Klebsiella pneumoniae*). Anaerobes (*Bacteroides* (n = 11), *Prevotella* (n = 8), *Clostridia* (n = 2) and *Fusobacteria* (n = 2)) were rare (total: n = 23, 6.7%). A fungal colonization (total: n = 15, 4.4%) was significantly more frequent with PBD+ (n = 13, 9%) than with PBD- (n = 2, 1%) (P < 0.01) and was always associated with the occurrence of at least one bacterial genus. Out of 15 fungi, 13 cases (87%) consisted of *Candida* spp.

With PBD+, there was a higher rate (86%) and variety of bacteria. The distribution of bacteria in the groups PBD+/PC- and PBD-/PC+ consisted of only 8 genera per group, but in among the PBD+, 18 genera were found for PBD+/PC- and 16 for PBD+/PC+. The TOP5 were most common in both PBD+ and PBD- [PBD+: n = 222 (75%) vs PBD-: n = 34 (74%), P = 0.87] (Table 2). In contrast, the Varia/other were found almost exclusively with PBD+ (n = 74, 86%). In Subgroup analysis of the most frequent (TOP5) bacteria, only *Enterococcus* was significantly more frequent in PBD+. A broad spectrum of bacteria and a polymicrobial colonization was significantly characteristic of PBD+ (Table 3).

The antimicrobial efficacy (AE) of the tested antibiotics in the whole group (n = 342) was 84% for imipenem, 74%/16% for piperacillin-tazobactam, 60%/26% for ampicillin-sulbactam, 43%/33% for ciprofloxacin, 59%/17% for moxifloxacin, 50%/22% for ceftriaxone, and 44%/39% cefuroxime. The outstanding AE of imipenem is also evident in the graphical representation of all four clinical groups. Piperacillin- tazobactam was only significantly more effective with PBD+/PC+ and PBD+/PC- than PAP with ampicillin-sulbactam. This in turn also differed significantly from ciprofloxacin, cefuroxime, and ceftriaxone. The sensitivity rates of the other substances were lower than those of the PAP. Moxifloxacin has a good AE similar to that of the PAP used (Table 3).

Compared to the clinically relevant substances (ampicillin-sulbactam and piperacillin-tazobactam), there was no significant difference in AE in enterococci, streptococci and *Klebsiella* spp. (together: n = 198; 57%). However, in *Escherichia* and *Enterobacter* spp. as well as in the rarer genera (together: n = 144, 43%), a significant difference in the AE was found. The AE of PAP was lower in about half of the bacteria in direct comparison of the two named substances (Table 5).

**DISCUSSION**

BB often occurs after interventions on the bile duct system. A preoperative ERCP is the typical trigger<sup>[21-31]</sup>. Prophylactic use of antibiotics as part of ERCP cannot reliably affect BB or cholangitis. Again, even biliary excreted Ciprofloxacin does not provide
uniform protection against post-ERCP cholangitis\(^9\). The suspended sphincter function of the papilla of Vater leads to colonization and a pathogen shift in the hepatobiliary system\(^{1,14,15}\). In only a few cases of our data, BB was detected without prior ERCP. However, a high BB rate is typical in patients with PBD+. This may have consequences for perioperative antibiotic prophylaxis (PAP). For pancreatic surgery, ampicillin-sulbactam is used for PAP in our clinic. It is not clear whether this strategy is sufficient for all patients prior to pancreatic resection. According to the recommendations of the guideline, no adaptation of the PAP depending on the PBD or PC status has been performed so far\(^{16}\).

The literature describes a BB rate of 87% and 98%, respectively, with PBD+ vs 21% and 55%, respectively, for PBD- and the frequent detection of a mixed flora with PBD+, which is in line with our own data. The introduction of a drain represents a risk independent of the presence of a preoperative cholestasis\(^{14}\). As PBD leads to an increase in postoperative complications, it shall not be performed routinely but only in selected cases\(^{17}\).

In a study of 91 ERCP patients, 15 different pathogen groups are identified, with Escherichia coli (28%) being the largest group\(^9\). In intraoperative smears of the hepatic duct, Klebsiella (18%), and enterococci spp. (13%) are the most frequent pathogens\(^6\). In patients with ERCP, enterococci spp. (31%) are most frequently detected with PBD+ and Escherichia coli (17%) with PBD-\(^{14}\). The literature also describes a shift to a more aggressive pathogen spectrum with an increase of *E. cloacae* and *E. faecalis*. At the same time, there is a lower sensitivity to ampicillin-sulbactam\(^9\). Therefore, it is recommended that an empirical PAP should take into account the more aggressive pathogen spectrum with PBD+. A significant increase of the mentioned genera was not found in our total of 342 bacteria. However, Enterococcus was significantly more frequent in PBD+ patients. The frequent detection of *Enterobacter* with PBD+ and the limited AE of ampicillin-sulbactam must be emphasized, too.

Of the antibiotics tested, imipenem is the most potent antibiotic substance. However, as it is an important reserve antibiotic, it should not be used for PAP. Our own data show a lower AE of ampicillin-sulbactam compared with piperacillin-tazobactam, depending on the implantation of a biliary drainage. The superiority of piperacillin-tazobactam is significantly detectable with PBD+. Same as Imipenem, this antibiotic has its place in treatment and not in prophylaxis. However, the AE of ampicillin-sulbactam stands out in comparison to the other substances examined and seems to be well suited to a PAP with PBD-.

Since anaerobes accounted for only 6% of the isolated genera, the administration of metronidazole in addition to the PAP does not seem to be necessary. In our data, the AE of moxifloxacin is comparable with that of the PAP. However, this substance has no indication with cholangitis.

In contrast to the guideline, adaptation of perioperative antibiotic therapy in the context of pancreatic surgery as a function of PBD status is recommended in the literature\(^{16,19}\). This is justified by an increase in infectious complications (especially wound infections) with PBD+\(^{1,20}\). However, severe complications or mortality are not affected by BB in this case\(^{21}\).

In our own data, there is often only one species with PBD-. In addition, the pathogen spectrum is less aggressive (rarely *Enterobacter* spp.). We categorize the group PBD-/PC- as a low risk group due to the low BB probability. There is a slightly higher risk (30%) of BB for PBD-/PC+ as well as a relative accumulation of rare pathogens, so that we assess the risk of this group as intermediate. We classify PBD+/PC- and PBD+/PC+ as high-risk groups, because BB with polymicrobial mixed flora is almost always found.

Based on the findings of the resistogram, the AE of the PAP is sufficient when used in low clinical-risk situations. It should be noted, however, that depending on the regional resistance situation, other preferences for the PAP may arise. Therefore,
Table 3  Bacterial profile in patients with bacteriobilia, (n = 150)

| Patients with…                          | PBD−, n (%) | PBD+, n (%) | P value |
|-----------------------------------------|-------------|-------------|---------|
| Polymicrobial mixed flora (n = 104)     | 12 (40)†    | 92 (78)     | < 0.01  |
| Enterococci (n = 82)                    | 9 (30)*     | 73 (61)     | < 0.05  |
| Streptococci (n = 41)                   | 6 (20)      | 35 (29)     | 0.32    |
| Klebsiella (n = 38)                     | 6 (20)      | 32 (27)     | 0.45    |
| Escherichia (n = 35)                    | 8 (27)      | 27 (23)     | 0.60    |
| Enterobacter (n = 21)                   | 1 (3)       | 20 (17)     | 0.06    |
| Multi-drug resistant bacteria (n = 4)   | 1 (3)       | 3 (3)       | 0.80    |

†P < 0.01 vs PBD−,  *P < 0.05 vs PBD+. PBD: Preoperative biliary drainage.

Continuous analysis and evaluation of the species isolated from the hepatocoduodenal duct is recommended.

On the basis of our data, a risk-adapted intensification to PAP with piperacillin-tazobactam may be seriously considered. In the literature, even with high risk, the recommendation is a primary 5-d therapy with later adjustment to the microbiological findings[23]. However, in our opinion, our own microbiological data do not allow this clinical conclusion. This would require the detection of significantly increased postinterventional infections with pathogens sensitive to piperacillin-tazobactam in this patient group. It is necessary to further analyze our own clinical data in this respect. In case of postoperative infection, these data have to be reminded in the selection of antibiotic treatment until the final results from the intraoperative smear are available.

In conclusion, A smear should always be taken intraoperatively during a pancreas head resection. This allows targeted subsequent antibiotic therapy in the perioperative course. The data of the clinical groups yield the following consequences: Patients with PBD+ are at high risk for polymicrobial bacteriobilia. Standard PAP may not sufficiently cover all genera in those patients. A significantly better antibiotic efficiency exists only for Imipenem and Piperacillin/Tazobactam. Their administration, however, can not be recommended for prophylactic use. An adequate alternative to our standard PAP can not be derived from our data.
### Table 4 Frequency of sensitivity and resistance compared to standard antibiotic prophylaxis with ampicillin-sulbactam in 342 bacteria

|                | Ampicillin Sulbactam | Imipenem | Piperacillin Tazobactam | Ciprofloxacin | Moxifloxacin | Ceftriaxon | Cefuroxim |
|----------------|-----------------------|----------|-------------------------|---------------|--------------|------------|-----------|
| **PBD+ (n = 296)** | Sensitivity | 174 (59) | 249 (84) | 219 (74) | 129 (44) | 173 (58) | 147 (50) | 126 (43) |
|                | Resistance | 81 (27)  | 31 (11) | 45 (15)  | 96 (32)  | 49 (17)  | 62 (21)  | 115 (39) |
| **PBD- (n = 46)** | Sensitivity | 31 (67)  | 37 (80) | 33 (72)  | 18 (39)  | 27 (59)  | 23 (50)  | 24 (52)  |
|                | Resistance | 8 (17)   | 7 (15)  | 8 (17)   | 15 (33)  | 8 (17)   | 13 (28)  | 18 (39)  |

Absolute numbers and percentages in brackets,

P < 0.01, P < 0.05. PBD: Preoperative biliary drainage.

### Table 5 Antimicrobial efficacy of ampicillin-sulbactam and piperacillin-tazobactam in direct comparison with 342 bacteria

|                  | Sensitivity (%) | Significance | Resistance (%) | Significance |
|------------------|-----------------|--------------|---------------|--------------|
| **TOPS (n = 256)** |                 |              |               |              |
| Enterococci (n = 97) | 71              | NS           | 27            | NS           |
| Streptococci (n = 58) | 60              | < 0.01       | 0             | NS           |
| Klebsiella (n = 43)   | 86              | NS           | 14            | 0.03         |
| Escherichia (n = 36)   | 81              | < 0.01       | 19            | 0.02         |
| Enterobacter (n = 22)   | 5               | < 0.01       | 95            | < 0.01       |
| Other genera       | 40              | < 0.01       | 34            | < 0.01       |

AS: Ampicillin-sulbactam; PT: Piperacillin-tazobactam; NS: No significance.

#P < 0.01 vs PT,

#P < 0.03 vs PT,

#P < 0.02 vs PT.
Figure 1  Proven sensitivities and resistances in the intraoperative smear of the hepatic duct. Out of 285 patients, pathogens were not detected in 134 of them. In 150 patients, 342 bacteria were detected and the associated sensitivity and resistance tests were compiled. PBD+/- and PC+/- according to the defined clinical groups is used as subtitle of the figures. A1: Ampicillin; A2: Ampicillin/Sulbactam; C1: Cefazolin; C2 – Ceftazidim; C3: Ceftriaxon; C4: Cefuroxim; C5: Ciprofloxacin; C6: Clindamycin; D: Doxycyclin; E: Erythromycin; F: Fosfomycin; G: Gentamycin; I: Imipenem; L: Linezolid; M1: Meropenem; M2: Moxifloxacin; O: Oxacillin; P1: Penicillin; P2: Piperacillin; P3: Piperacillin/Tazobactam; R: Rifampicin; T1: Tigecyclin; T2: Trimethoprim/Sulfamethoxazol; T3: Tobramycin; V: Vancomycin. PBD: Preoperative biliary drainage; PC: Preoperative cholestasis.

ARTICLE HIGHLIGHTS

Research background
Preoperative biliary drainage (PBD) is a common cause of bacterobilia (BB) and is a known surgical site infection risk factor, especially in pancreatoduodenectomies.

Research motivation
An adjustment of preoperative antibiotic prophylaxis (PAP) may be reasonable according to the profile of BB. However, current guidelines do not recommend an adoption of the PAP according to the PBD status.

Research objectives
The objective of this study was to analyze the bacterial profile in routine patients undergoing pancreatic surgery and to find out, if our PAP is adequate for our patients. Antibiotic efficiency was analyzed for standard PAP and possible alternatives.

Research methods
In the period from January 2009 to December 2015, 285 consecutive pancreatic head resections were performed. Indications for surgery were malignancy (71%), chronic pancreatitis (18%), and others (11%). A PBD was in 51% and preoperative cholestasis (PC) was in 42%. The standard PAP was ampicillin/subbactam. Intraoperatively, a smear was taken from the hepatic duct. Patients were categorized according to the existence or lack of PC (PC+/PC-) and PBD (PBD+/PBD-).

Research results
BB was present in 150 patients (53%). BB was significantly more frequent in PBD+ (n = 120) than in PBD- (n = 30), P < 0.01. BB was more frequent in malignancy (56%) than in chronic pancreatitis (45%). PBD, however, was the only independent risk factor for BB in multivariate analysis (P <
The five most common groups (n = 256, 74.8%) were Enterococcus spp. (28.4%), Streptococcus spp. (16.9%), Klebsiella spp. (12.6%), Escherichia coli (10.5%), and Enterobacter spp. (6.4%). A polymicrobial BB (PBD+: 77% vs PBD-: 40%, P < 0.01) and a more frequent detection of Enterococcus (P < 0.05) was significantly associated with PBD+. In PBD+, the efficiency of imipenem and piperacillin/tazobactam was significantly higher than that of standard PAP (P < 0.01).

**Research conclusions**
PBD-/PC- and PBD-/PC+ were associated with a low rate of BB, while PBD+ was always associated with a high rate of BB. In PBD+ patients, BB was polymicrobial and more often associated with Enterococcus. In PBD+, the spectrum of potential bacteria may not be covered by standard PAP. A more potent alternative for prophylactic application, however, was not found.

**Research perspectives**
The perspective of this study is to show more differentiated ways of perioperative antibiotic prophylaxis and to stratify patient groups according to BB and PC status. As patients with PBD+ are not fully covered by standard PAP, these patients have a well-known high risk for infectious complications. A more proper PAP is required. In these selected patients a primary antibiotic treatment adopted to the (suspected) resistogramm.

**REFERENCES**

1. Jinkins LJ, Parmar AD, Han Y, Duncan CB, Sheffield KM, Brown KM, Riall TS. Current trends in preoperative biliary stenting in patients with pancreatic cancer. *Surgery* 2013; 154: 179-189 [PMID: 23889947 DOI: 10.1016/j.surg.2013.03.016]

2. Ratanauc-ek T, Prapunphani P, Leelawat K, Chantawibul S, Panpinamas S, Subwongcharoen S, Wannaprasert J. Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography. *World J Gastroenterol* 2007; 13: 276-279 [PMID: 17220908 DOI: 10.3748/wjg.v13.i2.276]

3. Bai Y, Gao F, Gao J, Zou DW, Li ZS. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis: a meta-analysis. *Pancreas* 2009; 38: 126-130 [PMID: 19238021 DOI: 10.1097/MPA.0b013e318189fbd9]

4. Ceysens C, Frans JM, Christiaens PS, Van Steenbergen W, Peertemans WE. Recommendations for antibiotic prophylaxis before ERCPC: can we come to workable conclusions after review of the literature? *Acta Clin Belg* 2006; 61: 10-18 [PMID: 16673611 DOI: 10.1177/000159370606100102]

5. Mezir JJJ, Brennan MF, Basar RE, D’Angelica MI, Fong Y, DeMatteo RP, Jamagin WR, Allen PJ. A matched case-control study of preoperative biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified. *J Gastrointest Surg* 2009; 13: 2163-2169 [PMID: 19774423 DOI: 10.1007/s11605-009-1046-9]

6. Sahora K, Morales-Oyarvide V, Ferrone C, Fong ZV, Warshaw LA, Lillemoe KD, Fernández-del Castillo C. Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. *J Hepatobiliary Pancreat Sci* 2016; 23: 181-187 [PMID: 2676943 DOI: 10.1002/jhbs.322]

7. Nomura T, Shirai Y, Hatakeyama K. Enterococcal bacthilia in patients with malignant biliary obstruction. *Dig Dis Sci* 2000; 45: 2183-2186 [PMID: 11215736 DOI: 10.1023/A:1023663803312]

8. Adler G, Seuffertlin T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G, Hahn S, Heinemann V, Hohenberger W, Langrehr JM, Lutz MP, Miecke O, Neuhaus H, Neuhaus P, Oettle H, Schlag PM, Schmid R, Schneiger W, Schlotthmann K, Werner J, Werner J. Wiedenmann B, Kopp I. [S3-Guidelines "Endocrine pancreatic cancer" 2007]. *Z Gastroenterol* 2007; 45: 487-523 [PMID: 17607616 DOI: 10.1055/s-2007-963224]

9. Van der Gaag NA, Rauws EA, van Eijck CH, Brunsvold MJ, van der Harst E, Kebben FJ, Geraets JJ, Groen JC, Gerhards MF, de Hingh IH, Klinkenbijt JJ, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bonsuay PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. *N Engl J Med* 2010; 362: 129-137 [PMID: 20071072 DOI: 10.1056/NEJMoa0902510]

10. Kawarada Y, Higashiguchi T, Yokoi H, Vaidya P, Mizamoto R. Preoperative biliary drainage in obstructive jaundice. *Hepatogastroenterology* 1995; 42: 300-307 [PMID: 8586539]

11. Negm AA, Schott A, Vonberg RP, Weissemueller TJ, Schneider AS, Kubica S, Strassburg CP, Manns MP, Suerbaum S, Wedemeyer J, Lankisch TO. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. *Gastrointest Endosc* 2010; 72: 284-291 [PMID: 20542101 DOI: 10.1016/j.gie.2010.02.043]

12. Rerkamit R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. *Gastrointest Endosc* 2002; 56: 885-889 [PMID: 12447303 DOI: 10.1067/mge.2002.129604]

13. Scheufele F, Aichinger L, Jäger C, Demir IE, Schorn S, Sargut M, Erkan M, Kleeff J, Ceyssens C. Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. *J Gastrointest Surg* 2009; 13: 2163-2169 [PMID: 19774423 DOI: 10.1007/s11605-009-1046-9]

14. Johnson RC, Alhrendt SA. The case against preoperative biliary drainage with pancreatic resection. *HPB* (Oxford) 2006; 8: 426-431 [PMID: 18333997 DOI: 10.1080/13651820600840124]

15. Ertz-Archambault N, Keim P, Von Hoff D. Microbiome and pancreatic cancer: A comprehensive topic review of literature. *World J Gastroenterol* 2017; 23: 1899-1908 [PMID: 28348497 DOI: 10.3748/wjg.v23.i10.1899]

16. Herzog T, Belyaev O, Akkuzu R, Hölling J, Uhl W, Chromik AM. The Impact of Bile Duct Cultures on Surgical Site Infections in Pancreatic Surgery. *Surg Infect (Larchmt)* 2015; 16: 444-449 [PMID: 26110464 DOI: 10.1089/sur.2014.104]

17. Kaya M, Beştar B, Bączak F, Bączak F, Arslan EG, Kaplan MA. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients. *World J Gastroenterol* 2012; 18: 3585-3589 [PMID: 22826628 DOI: 10.3748/wjg.v18.i18.3585]

18. Fathi AH, Jackson T, Barati M, Eghbalish B, Siegel KA, Siegel CT. Extended Perioperative Antibiotic
Coverage in Conjunction with Intraoperative Bile Cultures Decreases Infectious Complications after Pancreatoduodenectomy. *HPB Surg* 2016; 2016: 3031749 [PMID: 27147813 DOI: 10.1155/2016/3031749]

19 Scheufele F, Schorn S, Demir IE, Sargut M, Tieftrunk E, Calavrezos L, Jäger C, Friess H, Ceyhan GO. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. *Surgery* 2017; 161: 939-950 [PMID: 28043693 DOI: 10.1016/j.surg.2016.11.001]

20 Sudo T, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, Ohge H, Sueda T. Perioperative antibiotics covering bile contamination prevent abdominal infectious complications after pancreatectoduodenectomy in patients with preoperative biliary drainage. *World J Surg* 2014; 38: 2952-2959 [PMID: 25022981 DOI: 10.1007/s00268-014-2688-7]

21 Mohammed S, Evans C, VanBuren G, Hodges SE, Silberfein E, Artinyan A, Mo Q, Issazadeh M, McElhany AL, Fisher WE. Treatment of bacteriobilia decreases wound infection rates after pancreaticoduodenectomy. *HPB (Oxford)* 2014; 16: 592-598 [PMID: 23992045 DOI: 10.1111/hpb.12170]

22 Morris-Stiff G, Tanjumaranane A, Tan YM, Shapey I, Bharti C, Mayer AD, Buckels JA, Bramhall SR, Mirza DF. Pre-operative stenting is associated with a higher prevalence of post-operative complications following pancreatoduodenectomy. *Int J Surg* 2011; 9: 145-149 [PMID: 21029795 DOI: 10.1016/j.ijsu.2010.10.008]

23 Sourrouille I, Gaujoux S, Lacave G, Bert F, Dokmaz S, Belghiti J, Paugam-Burtz C, Sauvanet A. Five days of postoperative antimicrobial therapy decreases infectious complications following pancreatoduodenectomy in patients at risk for bile contamination. *HPB (Oxford)* 2013; 15: 473-480 [PMID: 23458261 DOI: 10.1111/hpb.12012]
